Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
They are not approved for human consumption, clinical use, or diagnostic purposes
CONCLUSION The evidence supporting the use of GLP-1RAs in the treatment of BAD is limited
doi: 10.1038/s41575-023-00754-7 8 SchoonejansJMOzanneSE
In the SURPASS-2 trial published in the New England Journal of Medicine, participants treated with tirzepatide (5 mg, 10 mg, or 15 mg weekly) experienced reductions in fasting triglycerides from baseline over 40 weeks, with greater reductions generally seen at higher doses
Lifestyle Factors That Amplify Benefits Retatrutide produces impressive cardiovascular improvements on its own, but combining pharmacological intervention with lifestyle modification amplifies the benefits substantially
PMID 20209464
